Absci, a startup focused on developing generative AI antibody discovery technology, announced a potential $247 million partnership with pharma giant AstraZeneca to focus on expediting the discovery of novel cancer treatments with the help of genAI technology.
The project will leverage Absci's Integrated Drug Creation platform – which combines scalable wet lab technologies with AI, and facilitates...
